logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12017975 B1

PDFFull Text
Date of Patent:
Jun. 25, 2024

Filed:

Oct. 14, 2022

Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith

Applicant:

The University of British Columbia, Vancouver, CA;

Inventors:

Artem Tcherkassov, Vancouver, CA;

Paul S. Rennie, Richmond, CA;

Fuqiang Ban, Markham, CA;

Eric J. J. Leblanc, Vancouver, CA;

Lavinia A. Carabet, Burnaby, CA;

Nada Lallous, Vancouver, CA;

Kriti Singh, Vancouver, CA;

Helene Morin, Vancouver, CA;

Anh-Tien Ton, Vancouver, CA;

Assignee:

THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver, CA;

Attorney:

SALIWANCHIK, LLOYD & EISENSCHENK

Primary Examiner:

David K O'Dell

Int. Cl.
CPC ...
C07C 237/22 (2006.01); C07C 255/66 (2006.01); C07C 275/30 (2006.01); C07C 311/18 (2006.01); C07C 335/16 (2006.01); C07C 335/18 (2006.01); C07D 211/42 (2006.01); C07D 213/40 (2006.01); C07D 213/61 (2006.01); C07D 231/14 (2006.01); C07D 239/42 (2006.01); C07D 241/24 (2006.01); C07D 249/08 (2006.01); C07D 261/08 (2006.01); C07D 265/30 (2006.01); C07D 265/36 (2006.01); C07D 277/36 (2006.01); C07D 307/14 (2006.01); C07D 311/16 (2006.01); C07D 333/20 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 409/06 (2006.01); C07D 413/12 (2006.01); C07D 417/06 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07C 237/22 (2013.01); C07C 255/66 (2013.01); C07C 275/30 (2013.01); C07C 311/18 (2013.01); C07C 335/16 (2013.01); C07C 335/18 (2013.01); C07D 211/42 (2013.01); C07D 213/40 (2013.01); C07D 213/61 (2013.01); C07D 231/14 (2013.01); C07D 239/42 (2013.01); C07D 241/24 (2013.01); C07D 249/08 (2013.01); C07D 261/08 (2013.01); C07D 265/30 (2013.01); C07D 265/36 (2013.01); C07D 277/36 (2013.01); C07D 307/14 (2013.01); C07D 311/16 (2013.01); C07D 333/20 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/06 (2013.01); C07D 413/12 (2013.01); C07D 417/06 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

Find Patent Forward Citations

Loading…